Paper Details

  1. Home
  2. Paper Details

Profiling of mouse and human liver diseases identifies targets for therapeutic treatment of autoimmune hepatitis.

Author: AlexandropoulosKonstantina, CentaMonica, FielMaria Isabel, ThermidorChristelle

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study assessed T cell inflammation in human autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and non-alcoholic steatohepatitis (NASH). T cell infiltration and inflammatory pathways were present in human AIH and PSC, and to a lesser extent in NASH. While gene expression profiles differed, 52 genes were commonly upregulated, including JAK3 tyrosine kinase. Targeting T cell responses with the JAK inhibitor tofacitinib in a mouse model of AIH reduced hepatic T cell infiltration, AIH histopathology, and immune parameters. This suggests that targeting T cell responses in established hepatic autoimmune inflammation may be a feasible strategy for treating AIH and potentially other CLDs.
Paper Details　
Original Abstract of the Article :
Autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and non-alcoholic steatohepatitis (NASH) are chronic liver diseases (CLDs) of distinct etiologies that represent a public health risk with limited therapeutic options. A common feature among CLDs is an aggressive T cell response resul...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clim.2023.109807

データ提供：米国国立医学図書館（NLM）

Targeting T Cells in Autoimmune Hepatitis

The human liver, a vital organ, can be affected by a variety of diseases, like a fragile oasis in the desert. This study investigates the potential of targeting T cells, a type of immune cell, in treating autoimmune hepatitis (AIH), a chronic liver disease characterized by inflammation and destruction of liver tissue. The researchers, like explorers seeking a cure, conducted a comprehensive study involving both human and mouse models of AIH. They examined the role of T cell inflammation in various liver diseases and tested the effectiveness of targeting T cells with the JAK inhibitor tofacitinib in a mouse model of AIH.

A Promising New Approach

The study found that targeting T cells with tofacitinib reduced liver inflammation and improved liver function in the mouse model of AIH. This finding suggests that targeting T cells could be a promising new approach for treating AIH and potentially other chronic liver diseases. It opens new avenues for developing effective therapies that address the underlying immune dysregulation in these conditions.

Protecting Our Vital Oasis

This study is like a camel discovering a new source of water in the desert, providing a potential solution for treating chronic liver diseases. The findings suggest that targeting T cells could be a promising new approach for treating AIH and potentially other chronic liver diseases. This research is like a reminder to cherish and protect our vital organs, just as a camel cherishes its oasis.

Dr.Camel's Conclusion

This research, like a camel traversing the desert of liver disease, provides a valuable new perspective on treating autoimmune hepatitis. The study suggests that targeting T cells could be a promising new approach for treating AIH and potentially other chronic liver diseases. This study is a reminder that ongoing research is essential to find new and effective treatments for debilitating conditions like AIH.
Date :
  1. Date Completed 2023-11-06
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

37821072

DOI: Digital Object Identifier

10.1016/j.clim.2023.109807

Related Literature

Article Analysis
・Effective treatment of liver diseases
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.